MedTrace Logo

A Study of Probiotics Administration in the Immunotherapy of Urothelial Bladder Carcinoma

NCT05220124 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 190

Last updated 2022-02-02

No results posted yet for this study

Summary

A study of the efficacy and safety of probiotics in immunotherapy of urothelial carcinoma.

Conditions

  • Bladder Urothelial Carcinoma

Interventions

DRUG

Live Combined (Bifidobacterium,Lactobacillus and Enterococcus Capsules)

420mg Live Combined (Bifidobacterium,Lactobacillus and Enterococcus Capsules) bid for 4 treatment cycles.

Sponsors & Collaborators

  • Tianjin Medical University Second Hospital

    lead OTHER

Principal Investigators

  • Hailong Hu, MD,PhD · Tianjin Medical University Second Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-05
Primary Completion
2024-11-30
Completion
2024-11-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05220124 on ClinicalTrials.gov